<p>在过去三个月中，13 位分析师对 Zimmer Biomet Holdings（纽约证券交易所代码：ZBH）发布了从看涨到看跌的多样化评级。</p>
<p>下表提供了他们最近评级的简要概览，展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>分析师通过对 12 个月价格目标的评估提供了更深入的见解，揭示了平均目标为 101.08 美元，最高预估为 120.00 美元，最低预估为 86.00 美元。目前的平均价格目标较之前的平均价格目标下降了 3.94%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626848_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626848_0.png"/></p>
<h2>理解分析师评级：全面解析</h2>
<p>对近期分析师行动的深入分析揭示了金融专家对 Zimmer Biomet Holdings 的看法。以下总结概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>下调</td>
<td>卖出</td>
<td>$86.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>上调</td>
<td>市场表现</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>维持</td>
<td>买入</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>上调</td>
<td>超越市场</td>
<td>$120.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>下调</td>
<td>中性</td>
<td>$100.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>下调</td>
<td>中性</td>
<td>$94.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>下调</td>
<td>持有</td>
<td>$93.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>下调</td>
<td>卖出</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超越市场</td>
<td>$101.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下调</td>
<td>低配</td>
<td>$104.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>下调</td>
<td>中性</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下调</td>
<td>低配</td>
<td>$105.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>下调</td>
<td>买入</td>
<td>$112.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据市场动态和公司表现更新他们的建议。无论是'维持'、'上调'还是'下调'，都表明他们对 Zimmer Biomet Holdings 近期发展的反应。这为分析师对公司当前状态的看法提供了见解。</li>
<li><strong>评级：</strong> 分析师提供的定性见解揭示了股票表现，从'超越市场'到'低于市场'。这些评级传达了对 Zimmer Biomet Holdings 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 分析师设定价格目标作为对股票未来价值的估计。比较当前和之前的价格目标提供了分析师预期随时间变化的见解。这些信息对寻求了解股票潜在未来表现的投资者来说非常有价值。</li>
</ul>
<p>将这些分析师评估与相关财务指标结合分析，可以全面了解 Zimmer Biomet Holdings 的市场地位。保持信息灵通，并在我们的评级表的帮助下做出数据驱动的决策。</p>
<p>随时了解 Zimmer Biomet Holdings 的分析师评级。</p>
<h2>发现 Zimmer Biomet Holdings：更深入的了解</h2>
<p>Zimmer Biomet 设计、制造和销售骨科重建植入物，以及骨科手术所需的供应和手术设备。通过在 2003 年收购 Centerpulse 和在 2015 年收购 Biomet，Zimmer 在美国、欧洲和日本的重建市场中占据领先份额。大约三分之二的总收入来自大型关节的销售；另外四分之一来自四肢、创伤、运动医学和相关手术产品。该公司于 2022 年剥离了其牙科和脊柱业务。</p>
<h3>Zimmer Biomet Holdings：深入财务分析</h3>
<p><strong>市值视角：</strong> 该公司的市值低于行业平均水平，表明其相较于同行规模较小。这种定位可能受到感知增长潜力或运营规模等因素的影响。</p>
<p><strong>收入增长：</strong> Zimmer Biomet Holdings 在 2023 年第三季度表现出积极的结果。截至 2025 年 9 月 30 日，该公司实现了约 <strong>9.71%</strong> 的稳健收入增长率。这表明公司的营业收入显著增加。与行业同行相比，该公司的增长率低于医疗保健行业的平均水平。</p>
<p><strong>净利润率：</strong> 该公司的净利润率表现突出，超过行业平均水平。凭借 <strong>11.54%</strong> 的净利润率，该公司展示了强大的盈利能力和有效的成本控制。</p>
<p><strong>股本回报率（ROE）：</strong> 该公司的 ROE 低于行业基准，表明在有效利用股本方面可能存在困难。ROE 为 <strong>1.83%</strong>，公司可能需要解决为股东创造满意回报的挑战。</p>
<p><strong>资产回报率（ROA）：</strong> Zimmer Biomet Holdings 的 ROA 低于行业标准，表明在有效利用资产方面可能存在困难。ROA 为 <strong>1.0%</strong>，公司可能面临从其资产中提供满意回报的挑战。</p>
<p><strong>债务管理：</strong> Zimmer Biomet Holdings 的债务与股本比率低于平均水平，为 <strong>0.64</strong>，采取了谨慎的财务策略，表明其在债务管理方面采取了平衡的方法。</p>
<h2>分析师评级基础知识</h2>
<p>Benzinga 跟踪 150 家分析师公司并报告它们的股票预期。分析师通常通过预测公司未来的盈利能力，通常是接下来的五年，以及该公司的收入来源的风险性或可预测性，来得出结论。</p>
<p>分析师参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布他们对股票的评级。分析师通常每季度对每只股票进行一次评级，或者在公司有重大更新时进行评级。</p>
<p>一些分析师发布他们对增长预期、收益和收入等指标的预测，以提供额外的评级指导。在使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供自己的意见。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

<p>最近，十三位分析师对 Zimmer Biomet Holdings（纽约证券交易所代码：ZBH）进行了评级，显示出看涨和看跌情绪的混合。12 个月的平均目标价为 101.08 美元，比之前的估计下降了 3.94%。主要分析师调整了他们的评级，有些下调了目标价，有些则上调了。该公司的市值低于行业平均水平，但显示出强劲的盈利能力，净利润率为 11.54%。然而，其股本回报率和资产回报率低于行业基准，表明在资本效率方面可能面临挑战。Zimmer Biomet 专注于骨科重建植入物和外科设备</p>

<p>Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Zimmer Biomet Holdings (NYSE: ZBH) in the last three months.</p>
<div class="lb-trans"><p>在过去三个月中，13 位分析师对 Zimmer Biomet Holdings（纽约证券交易所代码：ZBH）发布了从看涨到看跌的多样化评级。</p>
</div><p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他们最近评级的简要概览，展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
</div><p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $101.08, a high estimate of $120.00, and a low estimate of $86.00. A decline of 3.94% from the prior average price target is evident in the current average.</p>
<div class="lb-trans"><p>分析师通过对 12 个月价格目标的评估提供了更深入的见解，揭示了平均目标为 101.08 美元，最高预估为 120.00 美元，最低预估为 86.00 美元。目前的平均价格目标较之前的平均价格目标下降了 3.94%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626848_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769626848_0.png"/></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<div class="lb-trans"><h2>理解分析师评级：全面解析</h2>
</div><p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Zimmer Biomet Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>对近期分析师行动的深入分析揭示了金融专家对 Zimmer Biomet Holdings 的看法。以下总结概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$86.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Maintains</td>
<td>Buy</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$93.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$101.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$104.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$105.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$112.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>下调</td>
<td>卖出</td>
<td>$86.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>上调</td>
<td>市场表现</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>维持</td>
<td>买入</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>上调</td>
<td>超越市场</td>
<td>$120.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>下调</td>
<td>中性</td>
<td>$100.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>下调</td>
<td>中性</td>
<td>$94.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>下调</td>
<td>持有</td>
<td>$93.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>下调</td>
<td>卖出</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超越市场</td>
<td>$101.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下调</td>
<td>低配</td>
<td>$104.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>下调</td>
<td>中性</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下调</td>
<td>低配</td>
<td>$105.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>下调</td>
<td>买入</td>
<td>$112.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zimmer Biomet Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据市场动态和公司表现更新他们的建议。无论是'维持'、'上调'还是'下调'，都表明他们对 Zimmer Biomet Holdings 近期发展的反应。这为分析师对公司当前状态的看法提供了见解。</li>
<li><strong>评级：</strong> 分析师提供的定性见解揭示了股票表现，从'超越市场'到'低于市场'。这些评级传达了对 Zimmer Biomet Holdings 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 分析师设定价格目标作为对股票未来价值的估计。比较当前和之前的价格目标提供了分析师预期随时间变化的见解。这些信息对寻求了解股票潜在未来表现的投资者来说非常有价值。</li>
</ul>
</div><p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Zimmer Biomet Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<div class="lb-trans"><p>将这些分析师评估与相关财务指标结合分析，可以全面了解 Zimmer Biomet Holdings 的市场地位。保持信息灵通，并在我们的评级表的帮助下做出数据驱动的决策。</p>
</div><p>Stay up to date on Zimmer Biomet Holdings analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Zimmer Biomet Holdings 的分析师评级。</p>
</div><h2>Discovering Zimmer Biomet Holdings: A Closer Look</h2>
<div class="lb-trans"><h2>发现 Zimmer Biomet Holdings：更深入的了解</h2>
</div><p>Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.</p>
<div class="lb-trans"><p>Zimmer Biomet 设计、制造和销售骨科重建植入物，以及骨科手术所需的供应和手术设备。通过在 2003 年收购 Centerpulse 和在 2015 年收购 Biomet，Zimmer 在美国、欧洲和日本的重建市场中占据领先份额。大约三分之二的总收入来自大型关节的销售；另外四分之一来自四肢、创伤、运动医学和相关手术产品。该公司于 2022 年剥离了其牙科和脊柱业务。</p>
</div><h3>Zimmer Biomet Holdings: Delving into Financials</h3>
<div class="lb-trans"><h3>Zimmer Biomet Holdings：深入财务分析</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值视角：</strong> 该公司的市值低于行业平均水平，表明其相较于同行规模较小。这种定位可能受到感知增长潜力或运营规模等因素的影响。</p>
</div><p><strong>Revenue Growth:</strong> Zimmer Biomet Holdings displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately <strong>9.71%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Zimmer Biomet Holdings 在 2023 年第三季度表现出积极的结果。截至 2025 年 9 月 30 日，该公司实现了约 <strong>9.71%</strong> 的稳健收入增长率。这表明公司的营业收入显著增加。与行业同行相比，该公司的增长率低于医疗保健行业的平均水平。</p>
</div><p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>11.54%,</strong> the company showcases strong profitability and effective cost control.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> 该公司的净利润率表现突出，超过行业平均水平。凭借 <strong>11.54%</strong> 的净利润率，该公司展示了强大的盈利能力和有效的成本控制。</p>
</div><p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.83%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> 该公司的 ROE 低于行业基准，表明在有效利用股本方面可能存在困难。ROE 为 <strong>1.83%</strong>，公司可能需要解决为股东创造满意回报的挑战。</p>
</div><p><strong>Return on Assets (ROA):</strong> Zimmer Biomet Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.0%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Zimmer Biomet Holdings 的 ROA 低于行业标准，表明在有效利用资产方面可能存在困难。ROA 为 <strong>1.0%</strong>，公司可能面临从其资产中提供满意回报的挑战。</p>
</div><p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.64</strong>, Zimmer Biomet Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Zimmer Biomet Holdings 的债务与股本比率低于平均水平，为 <strong>0.64</strong>，采取了谨慎的财务策略，表明其在债务管理方面采取了平衡的方法。</p>
</div><h2>The Basics of Analyst Ratings</h2>
<div class="lb-trans"><h2>分析师评级基础知识</h2>
</div><p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<div class="lb-trans"><p>Benzinga 跟踪 150 家分析师公司并报告它们的股票预期。分析师通常通过预测公司未来的盈利能力，通常是接下来的五年，以及该公司的收入来源的风险性或可预测性，来得出结论。</p>
</div><p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<div class="lb-trans"><p>分析师参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布他们对股票的评级。分析师通常每季度对每只股票进行一次评级，或者在公司有重大更新时进行评级。</p>
</div><p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<div class="lb-trans"><p>一些分析师发布他们对增长预期、收益和收入等指标的预测，以提供额外的评级指导。在使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供自己的意见。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

专家展望：13 位分析师眼中的 Zimmer Biomet Holdings